NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Prese...
November 04 2020 - 8:00AM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, today announced that multiple aldafermin
presentations, including a late-breaking oral presentation and
comprehensive data from its 24-week Phase 2 study (Cohort 4) of
aldafermin in patients with non-alcoholic steatohepatitis (NASH),
will be featured at AASLD’s The Liver Meeting®, being held
virtually Nov. 13-16, 2020.
Entitled “Aldafermin (NGM282) produces greater anti-fibrotic
response in patients with nonalcoholic steatohepatitis and advanced
fibrosis”, the late-breaking oral presentation (LO3) will be given
by Guy W. Neff, MD, MBA, FAASLD, Chief Executive Officer and
President of Covenant Research and Clinics, on Sunday, Nov. 15,
2020, 5:30 – 5:45 PM ET. The presentation will include detailed
findings from the 24-week Phase 2 study in subgroups of patients
who had stage 2 (F2) or stage 3 (F3) liver fibrosis at
baseline.
In addition, an oral presentation (072) entitled “Final analysis
of a 24-week, randomized, double-blind, placebo-controlled,
multicenter study of aldafermin (NGM282) in patients with
nonalcoholic steatohepatitis”, will be given by Stephen A.
Harrison, MD, Medical Director of Pinnacle Clinical Research,
Visiting Professor of Hepatology at University of Oxford, UK on
Sunday, Nov. 15, 2020, 10:20 – 10:45 AM ET. This presentation will
report on comprehensive data from the 24-week Phase 2 study,
including new analyses of C4, a marker of bile acid synthesis, as
well as serum bile acid changes from the study.
NGM will also have the following aldafermin-related poster
presentations at AASLD The Liver Meeting:
Poster Presentation
(1678)Abstract
title: Lipid Management in a 24-week, randomized,
double-blind, placebo-controlled study of aldafermin
(NGM282)Presenting author: Nadege T. Gunn, M.D.,
Physician Investigator, Gastroenterology/Hepatology, Pinnacle
Clinical Research, Austin, TexasDate and
time: Nov. 13, 2020, 6:00 AM – 11:55 PM ET
Poster Presentation
(1476)Abstract
title: Aldafermin (NGM282) improves APRI, FIB-4 and
other non-invasive measures in patients with nonalcoholic
steatohepatitisPresenting author: Manal F.
Abdelmalek, MD, MPH, FACG, Professor of Medicine in the Division of
Gastroenterology and Hepatology at Duke UniversityDate and
time: Nov. 13, 2020, 6:00 AM – 11:55 PM ET
All presentations will be available on the NGM Bio website at
https://www.ngmbio.com/rd/presentations-and-publications/.
About
Aldafermin
Aldafermin (formerly NGM282) is an engineered analog of the
human hormone FGF19 that is dosed once daily as a subcutaneous
injection and has generated robust preclinical and clinical
evidence supporting its ability to reduce liver fat content,
improve liver function, reverse fibrosis and resolve NASH by
targeting multiple pathogenic pathways of liver disease. NGM has
evaluated this wholly-owned therapeutic in over 500 healthy
volunteers and patients across multiple liver and metabolic
diseases, including more than 200 NASH patients.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and
developing novel therapeutics based on scientific understanding of
key biological pathways underlying liver and metabolic diseases,
retinal diseases and cancer. We leverage our biology-centric drug
discovery approach to uncover novel mechanisms of action and
generate proprietary insights that enable us to move rapidly into
proof-of-concept studies and deliver potential first-in-class
medicines to patients. At NGM, we aspire to operate one of the most
productive research and development engines in the
biopharmaceutical industry, with multiple programs in clinical
development. Visit us at www.ngmbio.com for more information.
Investor
Contact:Alex Schwartzir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2023 to Jul 2024